EGMN -- The selective and reversible platelet inhibitor elinogrel will advance to a 24,000-patient, phase III megatrial on the strength of its encouraging performance in the phase II trial INNOVATE-PCI and other studies.
EGMN -- The selective and reversible platelet inhibitor elinogrel will advance to a 24,000-patient, phase III megatrial on the strength of its encouraging performance in the phase II trial INNOVATE-PCI and other studies.